Internal Medicine, Endocrinology, Diabetes, & Metabolism · Holyoke, MA
NPI
1992739726
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
5
Medicare group memberships
Hospitals
2
Hospital affiliations
10 Hospital Dr Ste 104
Holyoke, MA, 01040
Phone (413) 534-2820
Groups this clinician bills Medicare through
Medicare paid, 2024
$19K
382 services
Medicare patients, 2024
247
Average age 71
Drug cost, 2024
$2.1M
4,062 prescriptions
Company payments, 2025
$42K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert J Cooper was code 99213 (office e&m - established), 228 times for 151 patients. In total Robert J Cooper billed 382 services in 7 codes, and Medicare paid $19K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-03-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Facility | 228 | 151 | $41.58 | $9,480 |
| 99214 Office E&M - Established | Facility | 83 | 59 | $60.91 | $5,055 |
| 99204 Office E&M - New | Facility | 29 | 29 | $100.70 | $2,920 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 15 | 14 | $13.39 | $201 |
By year: 2022 $20K for 294 services; 2023 $24K for 383 services; 2024 $19K for 382 services.
Medicare prescription drug claims, 2024
In 2024, the drug Robert J Cooper prescribed most often to Medicare patients was Levothyroxine Sodium, with 311 prescriptions and refills. In total Robert J Cooper wrote 4,062 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 311 | 530 | 62 | $2,464 |
| Mounjaro Tirzepatide | 268 | 300 | 49 | $315K |
| Trulicity Dulaglutide | 256 | 284 | 54 | $269K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 188 | 378 | 53 | $21K |
| Jardiance Empagliflozin | 179 | 211 | 29 | $119K |
| Atorvastatin Calcium Generic | 152 | 303 | 41 | $2,252 |
| Ozempic Semaglutide | 141 | 153 | 31 | $137K |
| Novolog Flexpen Insulin Aspart | 140 | 217 | 33 | $30K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 129 | 202 | 41 | $8,435 |
| Tresiba Flextouch U-200 Insulin Degludec | 119 | 142 | 22 | $80K |
| Metformin Hcl Generic | 97 | 185 | 25 | $1,263 |
| Tymlos Abaloparatide | 92 | 94 | 13 | $251K |
| Evenity (2 Syringes) Romosozumab-Aqqg | 87 | 87 | 21 | $214K |
| Synthroid Levothyroxine Sodium | 73 | 123 | 14 | $5,162 |
| Tresiba Flextouch U-100 Insulin Degludec | 70 | 133 | 23 | $48K |
Brand drugs: 2,411 claims; generic drugs: 1,133 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert J Cooper $42K ($42K in general payments such as food, travel and fees) from 14 companies. The largest payer was Abbott Laboratories with $21K.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 35 | $21K |
| Ascendis Pharma Endocrinology Inc ASND | 16 | $20K |
| TerSera Therapeutics LLC | 1 | $620 |
| Novo Nordisk Inc NVO | 4 | $71.22 |
| Lilly USA, LLC LLY | 3 | $59.59 |
| Tandem Diabetes Care, Inc. TNDM | 2 | $51.81 |
| Radius Health, Inc. | 2 | $46.21 |
| Sequel Med Tech, LLC | 1 | $29.6 |
| Intercept Pharmaceuticals, Inc. | 1 | $28.83 |
| CeQur Corporation | 1 | $25.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.